Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1887 of 6351
-
VR therapy takes on the voices in your head
Symptom relief Recruiting nowRationale: Auditory verbal hallucinations (AVH) - hearing voices that others cannot hear - are common in mental illnesses. For many people AVH are distressing, disabling and persistent, despite medication. Current psychological interventions show low to medium effects. Preliminar…
Sponsor: University Medical Center Groningen • Aim: Symptom relief
Last updated Jun 26, 2026 16:50 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control OngoingThis is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS…
Phase 1/2 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:32 UTC
-
New pill for PKU shows promise in early human testing
Disease control CompletedThe goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differ…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can early blood transfusions save more trauma victims?
Knowledge-focused CompletedBackground: Trauma is the leading cause of death in young adults worldwide and the most common causes of mortality are haemorrhage and brain injury. About 40% of trauma related deaths are due to massive haemorrhage and approximately 30% of trauma patients have an associated traum…
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Experimental drug cocktail targets relapsed leukemia
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). 8-Chloroadenosine may help bloc…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Chest infection showdown: drugs or surgery for empyema?
Disease control Recruiting nowPleura empyema is a frequent disease with a high morbidity and a mortality rate of approximately 15%. Pleura empyema is characterized by the passage of three stages (I - III). The aim of treating the disease is to remove the infection and provide fully expansion of the lung. Th…
Sponsor: Thomas Decker Christensen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a vaccine speed up TB recovery?
Disease control CompletedThis study is proposed to evaluate the safety and efficacy of the RUTI vaccine in patients with pulmonary tuberculosis. Therapeutic vaccination of RUTI would stimulate the immune response not only against growing bacteria, but also against bacteria in a latent state that are less…
Phase 2 • Sponsor: Archivel Farma S.L. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill combo aims to keep PNH patients stable for years
Disease control OngoingThis is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on Hard-to-Treat leukemia
Disease control OngoingThis phase I trial tests the safety, side effects, and best dose of entrectinib when given with ASTX727 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or that does not respond to treatment (refractory) and has a genetic change (mutation) in t…
Phase 1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy shows promise for tough-to-treat nose and throat cancer
Disease control CompletedThis study consists of two parts: Part 1 encompasses a safety lead - in phase and an expansion phase. In both phases, subjects with advanced nasopharyngeal carcinoma who have previously failed platinum - based chemotherapy and immune checkpoint inhibitors (such as anti - PD - 1 …
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New strategy aims to tame high blood pressure in HIV patients
Disease control CompletedThe Managing Hypertension Among People Living with HIV: An InTegrated Model (MAP-IT) a stepped wedge, cluster-randomized controlled trial to evaluate the effect of practice facilitation (PF) on the integration of a Task-Shifting Strategy for hypertension (HTN) control (TASSH) int…
Sponsor: Dr. Dike Ojji • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cocktail of cancer drugs shows promise in early lymphoma trial
Disease control OngoingThis study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Promising drug combo targets Hard-to-Treat amyloidosis
Disease control OngoingThe purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Zapping the brain to learn new words: a new frontier in speech therapy?
Knowledge-focused CompletedGroups of unimpaired participants will all receive speech motor training of nonwords, and six tDCS conditions will be compared: anodal tDCS over speech motor regions; cathodal tDCS over speech motor regions; anodal tDCS over left frontal regions; cathodal tDCS over left frontal r…
Sponsor: New York University • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
New stent aims to open blocked veins and heal leg ulcers
Disease control OngoingThis study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction wi…
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy takes on glioblastoma before surgery
Disease control Recruiting nowThis is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tece…
Early phase 1 • Sponsor: Stony Brook University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill could ease severe endometriosis pain
Symptom relief CompletedThe purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Phase 2 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New hope for kids with rare swelling disorder: daily pill may stop attacks
Disease control OngoingThe purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to \< 12 years of age for prophylactic treatment to prevent attacks of hereditary angioedema (H…
Phase 3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug trial hopes to slow muscle damage in kids with DMD
Disease control OngoingThe LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Phase 2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC